Effects of atorvastatin on serum lipid and hs-CRP,IL-6,TNF-α in elderly patients with hypertension
FANG Wei1, WEI Hongmei2, JIANG Aihua1, YANG Xixi2, ZHANG Tongle1
1. Department of Cardiology, Baoding First Central Hospital, Baoding 071000, China; 2. Department of Respiration, Anguo City Hospital, Anguo 071200, China
Abstract：Objective To investigate the influence of different doses atorvastatin on the serum lipid and high sensitive C-reactive protein ( hs-CRP ),IL-6,TNF-α in elderly patients with hypertension.Methods 120 elderly patients with hypertension were divided into three groups randomly: the control group,the atorvastatin treatment group 1 ( 10 mg/d) and the atorvastatin treatment group 2 ( 20 mg/d) . Each group received regular anti-hypertension treatment,the atorvastatin treatment groups were administered atrovastatin orally. Therapeutic time was 8 weeks. Blood pressure,TC,LDL-C,hs-CRP,IL-6,TNF-α contents were measured before and after therapy. Results Compared with before treatment, in the three groups after treatment, systolic blood pressure and diastolic blood pressure were significantly decreased (P<0.05). In the three groups of patients, TC, LDL-C, hs-CRP, IL-6 and TNF alpha all had varying degrees of decline, in treatment group 1 and group 2 decreased more significantly (P<0.05). TC in control group and treatment groups 1 and 2 were (5.89±0.53) mmol/L,(5.11±0.53) mmol/L and(4.92±0.23) mmol/L after treatment,respectively; LDL-C were(3.09±0.71) mmol/L,(2.69±0.33)mmol/L and(2.21±0.31) mmol/L; hs-CRP were(6.84±0.63) mg/L,(5.79±0.98 )mg/L and(4.49±1.01) mg/L. Compared with control group, in the two treatment groups, TC, LDL - C, hs CRP, IL 6 and TNF alpha significantly reduced, treatment 1 set of TC, LDL-C, hs-CRP significantly decreased (P<0.05). In treatment group 2, LCL-C and hs-CRP were significantly lower than in treatment group 1 (P< 0.05). Conclusions Atorvastatin can significantly reduce blood fat levels and inflammatory factor levels in the elderly patients with high blood pressure, and appropriate increase atorvastatin of dosage helps to improve curative effect, is worth promoting.
Kuklinska A M, Mroczko B. High-sensitivity C-reactive protein and total antioxidant status in patients with essential arterial hypertension and dyslipidemia [J]. Adv Med, 2009, 54(2): 225-232.
Charbonneau F, Anderson T J, Title L, et al. Modulation of arterial reactivity using amlodipine and atorvastat in measured by ultrasound examination[J]. Atherosclerosis, 2008, 197(1): 420 - 427.
Ridker P M. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease [J]. Criculation, 2011, 103: 1813-818.
2015, Vol. 26 
